newsfilter
← Latest News
GlobeNewswire·

Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates

Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio's R&D programs targeting the identification of novel therapeutics Entered into two new first phase feasibility programs with leading biopharma compan